Loading…
Reported covered position: Sr. FDA Counsel, US Senate Committee on Health, Education, Labor & Pensions.
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Consolidated Appropriations Act, 2023
Client: JOHNSON & JOHNSON SERVICES INC · Firm: COVINGTON & BURLING LLP
OTC drugs and cosmetics reform, including S. 2100, Personal Care Products Safety Act, S. 4338, FDASLA Act of 2022, H.R. 7667, Food & Drug Amendments of 2022, and H.R.2617, Consolidated Appropriations Act, 2023.
Consolidated Appropriations Act, 2023
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Consolidated Appropriations Act, 2023 (H.R.2617); Saving Access for Laboratory Services Act (S. 4449/H.R. 8188).
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2023 · first_quarter · 1A
Food and Drug Administration (FDA) and Centers for Medicare & Medicaid Services (CMS) policies related to diagnostics and laboratory regulation; reauthorization of the Pandemics and All-Hazards Preparedness Act (PAHPA).
GREENWICH BIOSCIENCES, INC. via COVINGTON & BURLING LLP
2022 · fourth_quarter · Q4
Source: Senate LDA
| BASIC AMERICAN INC |
| 2 |
| 2020 |
| CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2 | 2018 |
| MERCK & CO., INC. | 2 | 2018 |
| RWE ALLIANCE INC. | 2 | 2022 |
| CHANEL, INC. | 1 | 2019 |
Consolidated Appropriations Act, 2023
Client: PERSONAL CARE PRODUCTS COUNCIL · Firm: COVINGTON & BURLING LLP
Education and support for public policies to advance the modernization of FDA's regulation of cosmetics and OTC drugs; S.2100, Personal Care Products Safety Act; S. 3357, Humane Cosmetics Act; S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 7667, Food and Drug Amendments of 2022; H.R.2617, Consolidated Appropriations Act, 2023.
Consolidated Appropriations Act, 2023
Client: RWE ALLIANCE INC. · Firm: COVINGTON & BURLING LLP
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Consolidated Appropriations Act, 2023
Client: RWE ALLIANCE INC. · Firm: COVINGTON & BURLING LLP
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Consolidated Appropriations Act, 2023
Client: GREENWICH BIOSCIENCES, INC. · Firm: COVINGTON & BURLING LLP
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids; H.R. 841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; S. 4348, FDASLA Act of 2022; The Cannabis Administration and Opportunity Act (discussion draft); H.R.2617, Consolidated Appropriations Act, 2023.
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Consolidated Appropriations Act, 2023 (H.R.2617); Saving Access for Laboratory Services Act (S. 4449/H.R. 8188).
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Coronavirus impact and response.
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Coronavirus impact and response; FDASLA Act of 2022 (S. 4348).
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Coronavirus impact and response; FDASLA Act of 2022 (S. 4348); Food and Drug Amendments of 2022 (H.R.7667).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: RWE ALLIANCE INC. · Firm: COVINGTON & BURLING LLP
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: RWE ALLIANCE INC. · Firm: COVINGTON & BURLING LLP
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833).
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: RWE ALLIANCE INC. · Firm: COVINGTON & BURLING LLP
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: RWE ALLIANCE INC. · Firm: COVINGTON & BURLING LLP
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833).
Food and Drug Amendments of 2022
Client: JOHNSON & JOHNSON SERVICES INC · Firm: COVINGTON & BURLING LLP
OTC drugs and cosmetics reform, including S. 2100, Personal Care Products Safety Act, S. 4338, FDASLA Act of 2022, and H.R. 7667, Food & Drug Amendments of 2022
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833).
Food and Drug Amendments of 2022
Client: JOHNSON & JOHNSON SERVICES INC · Firm: COVINGTON & BURLING LLP
OTC drugs and cosmetics reform, including S. 2100, Personal Care Products Safety Act, S. 4338, FDASLA Act of 2022, and H.R. 7667, Food & Drug Amendments of 2022
Food and Drug Amendments of 2022
Client: PERSONAL CARE PRODUCTS COUNCIL · Firm: COVINGTON & BURLING LLP
Education and support for public policies to advance the modernization of FDA's regulation of cosmetics and OTC drugs; S.2100, Personal Care Products Safety Act; S. 3357, Humane Cosmetics Act; S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 7667, Food and Drug Amendments of 2022
Food and Drug Amendments of 2022
Client: PERSONAL CARE PRODUCTS COUNCIL · Firm: COVINGTON & BURLING LLP
Education and support for public policies to advance the modernization of FDA's regulation of cosmetics and OTC drugs; S.2100, Personal Care Products Safety Act; S. 3357, Humane Cosmetics Act; S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 7667, Food and Drug Amendments of 2022; H.R.2617, Consolidated Appropriations Act, 2023.
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833).
Food and Drug Amendments of 2022
Client: PERSONAL CARE PRODUCTS COUNCIL · Firm: COVINGTON & BURLING LLP
Education and support for public policies to advance the modernization of FDA's regulation of cosmetics and OTC drugs; S.2100, Personal Care Products Safety Act; S. 3357, Humane Cosmetics Act; S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 7667, Food and Drug Amendments of 2022
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Food and Drug Amendments of 2022
Client: JOHNSON & JOHNSON SERVICES INC · Firm: COVINGTON & BURLING LLP
OTC drugs and cosmetics reform, including S. 2100, Personal Care Products Safety Act, S. 4338, FDASLA Act of 2022, H.R. 7667, Food & Drug Amendments of 2022, and H.R.2617, Consolidated Appropriations Act, 2023.
Food and Drug Amendments of 2022
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Coronavirus impact and response; FDASLA Act of 2022 (S. 4348); Food and Drug Amendments of 2022 (H.R.7667).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Saving Access to Laboratory Services Act
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Consolidated Appropriations Act, 2023 (H.R.2617); Saving Access for Laboratory Services Act (S. 4449/H.R. 8188).
Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021
Client: GREENWICH BIOSCIENCES, INC. · Firm: COVINGTON & BURLING LLP
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids; H.R. 841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; S. 4348, FDASLA Act of 2022; The Cannabis Administration and Opportunity Act (discussion draft).
Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021
Client: GREENWICH BIOSCIENCES, INC. · Firm: COVINGTON & BURLING LLP
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids; H.R. 841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; The Cannabis Administration and Opportunity Act (discussion draft).
Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021
Client: GREENWICH BIOSCIENCES, INC. · Firm: COVINGTON & BURLING LLP
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids; H.R. 841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; S. 4348, FDASLA Act of 2022; The Cannabis Administration and Opportunity Act (discussion draft); H.R.2617, Consolidated Appropriations Act, 2023.
Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021
Client: GREENWICH BIOSCIENCES, INC. · Firm: COVINGTON & BURLING LLP
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids; H.R. 841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; S. 4348, FDASLA Act of 2022; The Cannabis Administration and Opportunity Act (discussion draft).
Personal Care Products Safety Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: COVINGTON & BURLING LLP
OTC drugs and cosmetics reform, including S. 2100, Personal Care Products Safety Act, S. 4338, FDASLA Act of 2022, and H.R. 7667, Food & Drug Amendments of 2022
Personal Care Products Safety Act
Client: PERSONAL CARE PRODUCTS COUNCIL · Firm: COVINGTON & BURLING LLP
Education and support for public policies to advance the modernization of FDA's regulation of cosmetics and OTC drugs; S.2100, Personal Care Products Safety Act; S. 3357, Humane Cosmetics Act; S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 7667, Food and Drug Amendments of 2022; H.R.2617, Consolidated Appropriations Act, 2023.
Personal Care Products Safety Act
Client: PERSONAL CARE PRODUCTS COUNCIL · Firm: COVINGTON & BURLING LLP
Education and support for public policies to advance the modernization of FDA's regulation of cosmetics and OTC drugs; S.2100, Personal Care Products Safety Act; S. 3357, Humane Cosmetics Act; S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 7667, Food and Drug Amendments of 2022
Personal Care Products Safety Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: COVINGTON & BURLING LLP
OTC drugs and cosmetics reform, including S. 2100, Personal Care Products Safety Act, S. 4338, FDASLA Act of 2022, and H.R. 7667, Food & Drug Amendments of 2022
Personal Care Products Safety Act
Client: PERSONAL CARE PRODUCTS COUNCIL · Firm: COVINGTON & BURLING LLP
Education and support for public policies to advance the modernization of FDA's regulation of cosmetics and OTC drugs; S.2100, Personal Care Products Safety Act
Personal Care Products Safety Act
Client: PERSONAL CARE PRODUCTS COUNCIL · Firm: COVINGTON & BURLING LLP
Education and support for public policies to advance the modernization of FDA's regulation of cosmetics and OTC drugs; S.2100, Personal Care Products Safety Act; S. 3357, Humane Cosmetics Act; S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 7667, Food and Drug Amendments of 2022
Personal Care Products Safety Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: COVINGTON & BURLING LLP
OTC drugs and cosmetics reform, including S. 2100, Personal Care Products Safety Act, S. 4338, FDASLA Act of 2022, H.R. 7667, Food & Drug Amendments of 2022, and H.R.2617, Consolidated Appropriations Act, 2023.
Personal Care Products Safety Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: COVINGTON & BURLING LLP
OTC drugs and cosmetics reform, including S. 2100, Personal Care Products Safety Act
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Coronavirus impact and response.
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Consolidated Appropriations Act, 2023 (H.R.2617); Saving Access for Laboratory Services Act (S. 4449/H.R. 8188).
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Coronavirus impact and response; FDASLA Act of 2022 (S. 4348).
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Coronavirus impact and response; FDASLA Act of 2022 (S. 4348); Food and Drug Amendments of 2022 (H.R.7667).
Humane Cosmetics Act of 2021
Client: PERSONAL CARE PRODUCTS COUNCIL · Firm: COVINGTON & BURLING LLP
Education and support for public policies to advance the modernization of FDA's regulation of cosmetics and OTC drugs; S.2100, Personal Care Products Safety Act; S. 3357, Humane Cosmetics Act; S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 7667, Food and Drug Amendments of 2022
Humane Cosmetics Act of 2021
Client: PERSONAL CARE PRODUCTS COUNCIL · Firm: COVINGTON & BURLING LLP
Education and support for public policies to advance the modernization of FDA's regulation of cosmetics and OTC drugs; S.2100, Personal Care Products Safety Act; S. 3357, Humane Cosmetics Act; S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 7667, Food and Drug Amendments of 2022; H.R.2617, Consolidated Appropriations Act, 2023.
Humane Cosmetics Act of 2021
Client: PERSONAL CARE PRODUCTS COUNCIL · Firm: COVINGTON & BURLING LLP
Education and support for public policies to advance the modernization of FDA's regulation of cosmetics and OTC drugs; S.2100, Personal Care Products Safety Act; S. 3357, Humane Cosmetics Act; S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 7667, Food and Drug Amendments of 2022
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
PREVENT Pandemics Act
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Coronavirus impact and response; FDASLA Act of 2022 (S. 4348); Food and Drug Amendments of 2022 (H.R.7667).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833).
PREVENT Pandemics Act
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Coronavirus impact and response; FDASLA Act of 2022 (S. 4348).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833).
PREVENT Pandemics Act
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Coronavirus impact and response.
PREVENT Pandemics Act
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Consolidated Appropriations Act, 2023 (H.R.2617); Saving Access for Laboratory Services Act (S. 4449/H.R. 8188).
Increasing Transparency in Generic Drug Applications Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: COVINGTON & BURLING LLP
OTC drugs and cosmetics reform, including S. 2100, Personal Care Products Safety Act, S. 4338, FDASLA Act of 2022, and H.R. 7667, Food & Drug Amendments of 2022
Increasing Transparency in Generic Drug Applications Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: COVINGTON & BURLING LLP
OTC drugs and cosmetics reform, including S. 2100, Personal Care Products Safety Act, S. 4338, FDASLA Act of 2022, H.R. 7667, Food & Drug Amendments of 2022, and H.R.2617, Consolidated Appropriations Act, 2023.
Increasing Transparency in Generic Drug Applications Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: COVINGTON & BURLING LLP
OTC drugs and cosmetics reform, including S. 2100, Personal Care Products Safety Act, S. 4338, FDASLA Act of 2022, and H.R. 7667, Food & Drug Amendments of 2022
Education and support for public policies to advance the modernization of FDA's regulation of cosmetics and OTC drugs; S.2100, Personal Care Products Safety Act; S. 3357, Humane Cosmetics Act; S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 7667, Food and Drug Amendments of 2022
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids; H.R. 841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; S. 4348, FDASLA Act of 2022; The Cannabis Administration and Opportunity Act (discussion draft).
FDASLA Act of 2022
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Coronavirus impact and response; FDASLA Act of 2022 (S. 4348); Food and Drug Amendments of 2022 (H.R.7667).
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids; H.R. 841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; S. 4348, FDASLA Act of 2022; The Cannabis Administration and Opportunity Act (discussion draft); H.R.2617, Consolidated Appropriations Act, 2023.
FDASLA Act of 2022
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Coronavirus impact and response; FDASLA Act of 2022 (S. 4348).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Education and support for public policies to advance the modernization of FDA's regulation of cosmetics and OTC drugs; S.2100, Personal Care Products Safety Act; S. 3357, Humane Cosmetics Act; S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 7667, Food and Drug Amendments of 2022; H.R.2617, Consolidated Appropriations Act, 2023.
Education and support for public policies to advance the modernization of FDA's regulation of cosmetics and OTC drugs; S.2100, Personal Care Products Safety Act; S. 3357, Humane Cosmetics Act; S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 7667, Food and Drug Amendments of 2022
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833).
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids; H.R. 841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; S. 4348, FDASLA Act of 2022; The Cannabis Administration and Opportunity Act (discussion draft).
Saving Access to Laboratory Services Act
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Consolidated Appropriations Act, 2023 (H.R.2617); Saving Access for Laboratory Services Act (S. 4449/H.R. 8188).
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); Coronavirus impact and response.
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Appropriations funding in response to COVID pandemic; Medicare funding; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128)
Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021
Client: GREENWICH BIOSCIENCES, INC. · Firm: COVINGTON & BURLING LLP
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids; H.R. 841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; The Cannabis Administration and Opportunity Act (discussion draft).
Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021
Client: GREENWICH BIOSCIENCES, INC. · Firm: COVINGTON & BURLING LLP
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids; H.R. 841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; The Cannabis Administration and Opportunity Act (discussion draft).
Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021
Client: GREENWICH BIOSCIENCES, INC. · Firm: COVINGTON & BURLING LLP
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids; H.R. 841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021
Personal Care Products Safety Act
Client: PERSONAL CARE PRODUCTS COUNCIL · Firm: COVINGTON & BURLING LLP
Education and support for public policies to advance the modernization of FDA's regulation of cosmetics and OTC drugs; S.2100, Personal Care Products Safety Act
Personal Care Products Safety Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: COVINGTON & BURLING LLP
OTC drugs and cosmetics reform, including S. 2100, Personal Care Products Safety Act
Personal Care Products Safety Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: COVINGTON & BURLING LLP
OTC drugs and cosmetics reform, including S. 2100, Personal Care Products Safety Act
Personal Care Products Safety Act
Client: PERSONAL CARE PRODUCTS COUNCIL · Firm: COVINGTON & BURLING LLP
Education and support for public policies to advance the modernization of FDA's regulation of cosmetics and OTC drugs; S.2100, Personal Care Products Safety Act
Personal Care Products Safety Act
Client: PERSONAL CARE PRODUCTS COUNCIL · Firm: COVINGTON & BURLING LLP
Education and support for public policies to advance the modernization of FDA's regulation of cosmetics and OTC drugs; S.2100, Personal Care Products Safety Act
Personal Care Products Safety Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: COVINGTON & BURLING LLP
OTC drugs and cosmetics reform, including S. 2100, Personal Care Products Safety Act
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); Coronavirus impact and response.
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Appropriations funding in response to COVID pandemic; Medicare funding; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128)
Children’s Product Warning Label Act of 2019
Client: JOHNSON & JOHNSON SERVICES INC · Firm: COVINGTON & BURLING LLP
OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 726), Cosmetic Safety Enhancement Act of 2019 (H.R. 5279), Children's Products Warning Label Act of 2019 (H.R. 1816)
Children’s Product Warning Label Act of 2019
Client: JOHNSON & JOHNSON SERVICES INC · Firm: COVINGTON & BURLING LLP
OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 726), Cosmetic Safety Enhancement Act of 2019 (H.R. 5279), Children's Products Warning Label Act of 2019 (H.R. 1816)
Children’s Product Warning Label Act of 2019
Client: JOHNSON & JOHNSON SERVICES INC · Firm: COVINGTON & BURLING LLP
OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 726), Cosmetic Safety Enhancement Act of 2019 (H.R. 5279), Children's Products Warning Label Act of 2019 (H.R. 1816)
Children’s Product Warning Label Act of 2019
Client: JOHNSON & JOHNSON SERVICES INC · Firm: COVINGTON & BURLING LLP
OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 726), Cosmetic Safety Enhancement Act of 2019 (H.R. 5279), Division B- Over the Counter Monograph Safety, Innovation and Reform provisions of The Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019 (H.R. 269), Children's Products Warning Label Act of 2019 (H.R. 1816)
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019
Client: JOHNSON & JOHNSON SERVICES INC · Firm: COVINGTON & BURLING LLP
OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 726), Cosmetic Safety Enhancement Act of 2019 (H.R. 5279), Division B- Over the Counter Monograph Safety, Innovation and Reform provisions of The Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019 (H.R. 269), Children's Products Warning Label Act of 2019 (H.R. 1816)
Medical Marijuana Research Act
Client: GREENWICH BIOSCIENCES, INC. · Firm: COVINGTON & BURLING LLP
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids, including H.R. 3797, The Medical Marijuana Research Act of 2019.
Medical Marijuana Research Act
Client: GREENWICH BIOSCIENCES, INC. · Firm: COVINGTON & BURLING LLP
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids, including H.R. 3797, The Medical Marijuana Research Act of 2019.
Humane Cosmetics Act of 2019
Client: PERSONAL CARE PRODUCTS COUNCIL · Firm: COVINGTON & BURLING LLP
OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 726), Humane Cosmetics Act (H.R. 5141/S. 2886), Cosmetic Safety Enhancement Act of 2019 (H.R. 5279). The FDA's proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
Humane Cosmetics Act of 2019
Client: PERSONAL CARE PRODUCTS COUNCIL · Firm: COVINGTON & BURLING LLP
OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 726), Humane Cosmetics Act (H.R. 5141/S. 2886), Cosmetic Safety Enhancement Act of 2019 (H.R. 5279). The FDA's proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
Humane Cosmetics Act of 2019
Client: PERSONAL CARE PRODUCTS COUNCIL · Firm: COVINGTON & BURLING LLP
OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 726), Humane Cosmetics Act (H.R. 5141/S. 2886), Cosmetic Safety Enhancement Act of 2019 (H.R. 5279). The FDA's proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
Cosmetic Safety Enhancement Act of 2019
Client: PERSONAL CARE PRODUCTS COUNCIL · Firm: COVINGTON & BURLING LLP
OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 726), Humane Cosmetics Act (H.R. 5141/S. 2886), Cosmetic Safety Enhancement Act of 2019 (H.R. 5279). The FDA's proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
Cosmetic Safety Enhancement Act of 2019
Client: JOHNSON & JOHNSON SERVICES INC · Firm: COVINGTON & BURLING LLP
OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 726), Cosmetic Safety Enhancement Act of 2019 (H.R. 5279), Children's Products Warning Label Act of 2019 (H.R. 1816)
Cosmetic Safety Enhancement Act of 2019
Client: JOHNSON & JOHNSON SERVICES INC · Firm: COVINGTON & BURLING LLP
OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 726), Cosmetic Safety Enhancement Act of 2019 (H.R. 5279), Children's Products Warning Label Act of 2019 (H.R. 1816)
Cosmetic Safety Enhancement Act of 2019
Client: PERSONAL CARE PRODUCTS COUNCIL · Firm: COVINGTON & BURLING LLP
OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 726), Humane Cosmetics Act (H.R. 5141/S. 2886), Cosmetic Safety Enhancement Act of 2019 (H.R. 5279). The FDA's proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids; H.R. 841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; S. 4348, FDASLA Act of 2022; The Cannabis Administration and Opportunity Act (discussion draft); H.R.2617, Consolidated Appropriations Act, 2023.
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2022 · fourth_quarter · Q4
Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Consolidated Appropriations Act, 2023 (H.R.2617); Saving Access for Laboratory Services Act (S. 4449/H.R. 8188).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PERSONAL CARE PRODUCTS COUNCIL via COVINGTON & BURLING LLP
2022 · fourth_quarter · Q4
Education and support for public policies to advance the modernization of FDA's regulation of cosmetics and OTC drugs; S.2100, Personal Care Products Safety Act; S. 3357, Humane Cosmetics Act; S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 7667, Food and Drug Amendments of 2022; H.R.2617, Consolidated Appropriations Act, 2023.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RWE ALLIANCE INC. via COVINGTON & BURLING LLP
2022 · fourth_quarter · Q4
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES INC via COVINGTON & BURLING LLP
2022 · fourth_quarter · Q4
OTC drugs and cosmetics reform, including S. 2100, Personal Care Products Safety Act, S. 4338, FDASLA Act of 2022, H.R. 7667, Food & Drug Amendments of 2022, and H.R.2617, Consolidated Appropriations Act, 2023.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VALNEVA USA, INC. via COVINGTON & BURLING LLP
2022 · fourth_quarter · Q4
Coverage of CDC recommended vaccines.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VALNEVA USA, INC. via COVINGTON & BURLING LLP
2022 · third_quarter · Q3
Coverage of CDC recommended vaccines.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2022 · third_quarter · Q3
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Coronavirus impact and response; FDASLA Act of 2022 (S. 4348); Food and Drug Amendments of 2022 (H.R.7667).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RWE ALLIANCE INC. via COVINGTON & BURLING LLP
2022 · third_quarter · Q3
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PERSONAL CARE PRODUCTS COUNCIL via COVINGTON & BURLING LLP
2022 · third_quarter · Q3
Education and support for public policies to advance the modernization of FDA's regulation of cosmetics and OTC drugs; S.2100, Personal Care Products Safety Act; S. 3357, Humane Cosmetics Act; S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 7667, Food and Drug Amendments of 2022
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GREENWICH BIOSCIENCES, INC. via COVINGTON & BURLING LLP
2022 · third_quarter · Q3
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids; H.R. 841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; S. 4348, FDASLA Act of 2022; The Cannabis Administration and Opportunity Act (discussion draft).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES INC via COVINGTON & BURLING LLP
2022 · third_quarter · Q3
OTC drugs and cosmetics reform, including S. 2100, Personal Care Products Safety Act, S. 4338, FDASLA Act of 2022, and H.R. 7667, Food & Drug Amendments of 2022
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2022 · second_quarter · Q2
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Coronavirus impact and response; FDASLA Act of 2022 (S. 4348).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VALNEVA USA, INC. via COVINGTON & BURLING LLP
2022 · second_quarter · Q2
Coverage of CDC recommended vaccines.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PERSONAL CARE PRODUCTS COUNCIL via COVINGTON & BURLING LLP
2022 · second_quarter · Q2
Education and support for public policies to advance the modernization of FDA's regulation of cosmetics and OTC drugs; S.2100, Personal Care Products Safety Act; S. 3357, Humane Cosmetics Act; S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 7667, Food and Drug Amendments of 2022
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GREENWICH BIOSCIENCES, INC. via COVINGTON & BURLING LLP
2022 · second_quarter · Q2
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids; H.R. 841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; S. 4348, FDASLA Act of 2022; The Cannabis Administration and Opportunity Act (discussion draft).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES INC via COVINGTON & BURLING LLP
2022 · second_quarter · Q2
OTC drugs and cosmetics reform, including S. 2100, Personal Care Products Safety Act, S. 4338, FDASLA Act of 2022, and H.R. 7667, Food & Drug Amendments of 2022
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2022 · first_quarter · Q1
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Coronavirus impact and response.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
VALNEVA USA, INC. via COVINGTON & BURLING LLP
2022 · first_quarter · Q1
Coverage of CDC recommended vaccines.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PERSONAL CARE PRODUCTS COUNCIL via COVINGTON & BURLING LLP
2022 · first_quarter · Q1
Education and support for public policies to advance the modernization of FDA's regulation of cosmetics and OTC drugs; S.2100, Personal Care Products Safety Act
Filing targets: SENATE
GREENWICH BIOSCIENCES, INC. via COVINGTON & BURLING LLP
2022 · first_quarter · Q1
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids; H.R. 841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; The Cannabis Administration and Opportunity Act (discussion draft).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES INC via COVINGTON & BURLING LLP
2022 · first_quarter · Q1
OTC drugs and cosmetics reform, including S. 2100, Personal Care Products Safety Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2021 · fourth_quarter · Q4
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); Coronavirus impact and response.
Filing targets: Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
PERSONAL CARE PRODUCTS COUNCIL via COVINGTON & BURLING LLP
2021 · fourth_quarter · Q4
Education and support for public policies to advance the modernization of FDA's regulation of cosmetics and OTC drugs; S.2100, Personal Care Products Safety Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GREENWICH BIOSCIENCES, INC. via COVINGTON & BURLING LLP
2021 · fourth_quarter · Q4
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids; H.R. 841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; The Cannabis Administration and Opportunity Act (discussion draft).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VALNEVA USA, INC. via COVINGTON & BURLING LLP
2021 · fourth_quarter · Q4
Coverage of CDC recommended vaccines.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
JOHNSON & JOHNSON SERVICES INC via COVINGTON & BURLING LLP
2021 · fourth_quarter · Q4
OTC drugs and cosmetics reform, including S. 2100, Personal Care Products Safety Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2021 · third_quarter · Q3
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Coronavirus impact and response.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
VALNEVA USA, INC. via COVINGTON & BURLING LLP
2021 · third_quarter · Q3
Coverage of CDC recommended vaccines.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PERSONAL CARE PRODUCTS COUNCIL via COVINGTON & BURLING LLP
2021 · third_quarter · Q3
Education and support for public policies to advance the modernization of FDA's regulation of cosmetics and OTC drugs; S.2100, Personal Care Products Safety Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GREENWICH BIOSCIENCES, INC. via COVINGTON & BURLING LLP
2021 · third_quarter · Q3
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids; H.R. 841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; The Cannabis Administration and Opportunity Act (discussion draft).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES INC via COVINGTON & BURLING LLP
2021 · third_quarter · Q3
OTC drugs and cosmetics reform, including S. 2100, Personal Care Products Safety Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2021 · second_quarter · Q2
Appropriations funding in response to COVID pandemic; Medicare funding
Appropriations funding in response to COVID pandemic; Medicare funding; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128)
Appropriations funding in response to COVID pandemic; Medicare funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PERSONAL CARE PRODUCTS COUNCIL via COVINGTON & BURLING LLP
2021 · second_quarter · Q2
Education and support for public policies to advance the modernization of FDA's regulation of cosmetics and OTC drugs; S.2100, Personal Care Products Safety Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES INC via COVINGTON & BURLING LLP
2021 · second_quarter · Q2
OTC drugs and cosmetics reform, including S. 2100, Personal Care Products Safety Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GREENWICH BIOSCIENCES, INC. via COVINGTON & BURLING LLP
2021 · second_quarter · Q2
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids; H.R. 841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PERSONAL CARE PRODUCTS COUNCIL via COVINGTON & BURLING LLP
2021 · first_quarter · Q1
Education and support for public policies to advance the modernization of FDA's regulation of cosmetics and OTC drugs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GREENWICH BIOSCIENCES, INC. via COVINGTON & BURLING LLP
2021 · first_quarter · Q1
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2021 · first_quarter · Q1
Appropriations funding in response to COVID pandemic; Medicare funding
Appropriations funding in response to COVID pandemic; Medicare funding
Appropriations funding in response to COVID pandemic; Medicare funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES INC via COVINGTON & BURLING LLP
2021 · first_quarter · Q1
OTC drugs and cosmetics reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2020 · fourth_quarter · Q4
Appropriations funding in response to COVID pandemic; Medicare funding
Appropriations funding in response to COVID pandemic; Medicare funding
Appropriations funding in response to COVID pandemic; Medicare funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PERSONAL CARE PRODUCTS COUNCIL via COVINGTON & BURLING LLP
2020 · fourth_quarter · Q4
OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 726), Humane Cosmetics Act (H.R. 5141/S. 2886), Cosmetic Safety Enhancement Act of 2019 (H.R. 5279). The FDA's proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES INC via COVINGTON & BURLING LLP
2020 · fourth_quarter · Q4
OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 726), Cosmetic Safety Enhancement Act of 2019 (H.R. 5279), Children's Products Warning Label Act of 2019 (H.R. 1816)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GREENWICH BIOSCIENCES, INC. via COVINGTON & BURLING LLP
2020 · fourth_quarter · Q4
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids, including H.R. 3797, The Medical Marijuana Research Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GREENWICH BIOSCIENCES, INC. via COVINGTON & BURLING LLP
2020 · third_quarter · Q3
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids, including H.R. 3797, The Medical Marijuana Research Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2020 · third_quarter · Q3
Appropriations funding in response to COVID pandemic; Medicare funding
Appropriations funding in response to COVID pandemic; Medicare funding
Appropriations funding in response to COVID pandemic; Medicare funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PERSONAL CARE PRODUCTS COUNCIL via COVINGTON & BURLING LLP
2020 · third_quarter · Q3
OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 726), Humane Cosmetics Act (H.R. 5141/S. 2886), Cosmetic Safety Enhancement Act of 2019 (H.R. 5279). The FDA's proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES INC via COVINGTON & BURLING LLP
2020 · third_quarter · Q3
OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 726), Cosmetic Safety Enhancement Act of 2019 (H.R. 5279), Children's Products Warning Label Act of 2019 (H.R. 1816)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PERSONAL CARE PRODUCTS COUNCIL via COVINGTON & BURLING LLP
2020 · second_quarter · Q2
OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 726), Humane Cosmetics Act (H.R. 5141/S. 2886), Cosmetic Safety Enhancement Act of 2019 (H.R. 5279). The FDA's proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GREENWICH BIOSCIENCES, INC. via COVINGTON & BURLING LLP
2020 · second_quarter · Q2
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BASIC AMERICAN, INC. via COVINGTON & BURLING LLP
2020 · second_quarter · Q2
Implementation of the Paycheck Protection Program and the Coronavirus Aid, Relief, and Economic Security (CARES) Act; USDA Food Programs
Implementation of the Paycheck Protection Program and the Coronavirus Aid, Relief, and Economic Security (CARES) Act; USDA Food Programs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES INC via COVINGTON & BURLING LLP
2020 · second_quarter · Q2
OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 726), Cosmetic Safety Enhancement Act of 2019 (H.R. 5279), Children's Products Warning Label Act of 2019 (H.R. 1816)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2020 · second_quarter · Q2
Appropriations funding in response to COVID pandemic; Medicare funding
Appropriations funding in response to COVID pandemic; Medicare funding
Appropriations funding in response to COVID pandemic; Medicare funding
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, Treasury, Dept of
BASIC AMERICAN, INC. via COVINGTON & BURLING LLP
2020 · second_quarter · RR
Implementation of the Paycheck Protection Program and the Coronavirus Aid, Relief, and Economic Security (CARES) Act
Implementation of the Paycheck Protection Program and the Coronavirus Aid, Relief, and Economic Security (CARES) Act
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2020 · first_quarter · Q1
Appropriations funding in response to COVID pandemic; Medicare funding (*Brendan Parets did not lobby the U.S. Senate*)
Appropriations funding in response to COVID pandemic; Medicare funding (*Brendan Parets did not lobby the U.S. Senate*)
Appropriations funding in response to COVID pandemic; Medicare funding (*Brendan Parets did not lobby the U.S. Senate*)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, Treasury, Dept of, Vice President of the U.S.
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2020 · first_quarter · RA
Appropriations funding in response to COVID pandemic; Medicare funding
Appropriations funding in response to COVID pandemic; Medicare funding
PERSONAL CARE PRODUCTS COUNCIL via COVINGTON & BURLING LLP
2020 · first_quarter · Q1
OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 726), Humane Cosmetics Act, Cosmetic Safety Enhancement Act of 2019 (H.R. 5279). The FDA's proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES INC via COVINGTON & BURLING LLP
2020 · first_quarter · Q1
OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 726), Cosmetic Safety Enhancement Act of 2019 (H.R. 5279), Division B- Over the Counter Monograph Safety, Innovation and Reform provisions of The Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019 (H.R. 269), Children's Products Warning Label Act of 2019 (H.R. 1816)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GREENWICH BIOSCIENCES, INC. via COVINGTON & BURLING LLP
2020 · first_quarter · Q1
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES INC via COVINGTON & BURLING LLP
2019 · fourth_quarter · Q4
OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 726), Energy and Commerce Bipartisan Discussion Draft legislation to modernize regulatory framework for cosmetics and personal care products, Cosmetic Safety Enhancement Act of 2019 (H.R. 5279), Division B- Over the Counter Monograph Safety, Innovation and Reform provisions of The Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019 (H.R. 269), Children's Products Warning Label Act of 2019 (H.R. 1816)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PERSONAL CARE PRODUCTS COUNCIL via COVINGTON & BURLING LLP
2019 · fourth_quarter · Q4
OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 726), Energy and Commerce Bipartisan Discussion Draft legislation to modernize regulatory framework for cosmetics and personal care products, Humane Cosmetics Act, Cosmetic Safety Enhancement Act of 2019 (H.R. 5279). The FDA's proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GREENWICH BIOSCIENCES, INC. via COVINGTON & BURLING LLP
2019 · fourth_quarter · Q4
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PERSONAL CARE PRODUCTS COUNCIL via COVINGTON & BURLING LLP
2019 · third_quarter · Q3
OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 726), Energy and Commerce Bipartisan Discussion Draft legislation to modernize regulatory framework for cosmetics and personal care products, Humane Cosmetics Act. The FDA's proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES INC via COVINGTON & BURLING LLP
2019 · third_quarter · Q3
OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 726), Energy and Commerce Bipartisan Discussion Draft legislation to modernize regulatory framework for cosmetics and personal care products, Division B -Over the Counter Monograph Safety, Innovation and Reform provisions of The Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019 (H.R. 269), Children's Products Warning Label Act of 2019 (H.R. 1816)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GREENWICH BIOSCIENCES, INC. via COVINGTON & BURLING LLP
2019 · third_quarter · Q3
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids.
Filing targets: SENATE
PERSONAL CARE PRODUCTS COUNCIL via COVINGTON & BURLING LLP
2019 · second_quarter · Q2
OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 726), Energy and Commerce Bipartisan Discussion Draft legislation to modernize regulatory framework for cosmetics and personal care products. The FDA's proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES INC via COVINGTON & BURLING LLP
2019 · second_quarter · Q2
OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 726), Energy and Commerce Bipartisan Discussion Draft legislation to modernize regulatory framework for cosmetics and personal care products, Division B -Over the Counter Monograph Safety, Innovation and Reform provisions of The Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019 (H.R. 269), Children's Products Warning Label Act of 2019 (H.R. 1816)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GREENWICH BIOSCIENCES, INC. via COVINGTON & BURLING LLP
2019 · second_quarter · Q2
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids.
Filing targets: SENATE
CHANEL, INC. via COVINGTON & BURLING LLP
2019 · second_quarter · RR
Federal cosmetic legislation
GREENWICH BIOSCIENCES, INC. via COVINGTON & BURLING LLP
2019 · first_quarter · Q1
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids.
Filing targets: SENATE
PERSONAL CARE PRODUCTS COUNCIL via COVINGTON & BURLING LLP
2019 · first_quarter · Q1
OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 726), Energy and Commerce Bipartisan Discussion Draft legislation to modernize regulatory framework for cosmetics and personal care products. The FDA's proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES INC via COVINGTON & BURLING LLP
2019 · first_quarter · Q1
OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 726), Energy and Commerce Bipartisan Discussion Draft legislation to modernize regulatory framework for cosmetics and personal care products, Division B -Over the Counter Monograph Safety, Innovation and Reform provisions of The Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019 (H.R. 269), Children's Products Warning Label Act of 2019 (H.R. 1816)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GREENWICH BIOSCIENCES, INC. via COVINGTON & BURLING LLP
2019 · first_quarter · RR
FDA regulatory policies related to pharmaceuticals
PERSONAL CARE PRODUCTS COUNCIL via COVINGTON & BURLING LLP
2018 · fourth_quarter · Q4
Consumer product safety issues related to potential amendments to the FDA's regulatory authorities over cosmetics, including S. 1113, Personal Care Products Safety Act, S. 2003, FDA Cosmetic Safety and Modernization Act; and Modernization of Cosmetics Regulation Act of 2018 (Senate HELP Committee Discussion Draft).
Filing targets: SENATE
KIND LLC via COVINGTON & BURLING LLP
2018 · fourth_quarter · Q4
Federal activity regarding food labeling claims
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES INC via COVINGTON & BURLING LLP
2018 · fourth_quarter · Q4
OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 1113), FDA Cosmetic Safety and Modernization Act (S. 2003), Modernization of Cosmetics Regulation Act of 2018 (Senate HELP Committee Discussion Draft), Over-the-Counter Drug Safety, Innovation and Reform Act (S. 2315), and Over-the-Counter Monograph Safety, Innovation and Reform Act of 2018 (H.R. 5333)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO, INC via COVINGTON & BURLING LLP
2018 · third_quarter · Q3
H.R. 6294, the Re-Valuing Anti-Microbial Products Act of 2018
Filing targets: HOUSE OF REPRESENTATIVES
PERSONAL CARE PRODUCTS COUNCIL via COVINGTON & BURLING LLP
2018 · third_quarter · Q3
Consumer product safety issues related to potential amendments to the FDA's regulatory authorities over cosmetics, including S. 1113, Personal Care Products Safety Act, S. 2003, FDA Cosmetic Safety and Modernization Act; and Modernization of Cosmetics Regulation Act of 2018 (Senate HELP Committee Discussion Draft).
Filing targets: SENATE
MERCK & CO, INC via COVINGTON & BURLING LLP
2018 · third_quarter · RA
H.R. 6294, the Re-Valuing Anti-Microbial Products Act of 2018
CONSUMER HEALTHCARE PRODUCTS ASSOCIATION via COVINGTON & BURLING LLP
2018 · third_quarter · Q3
Regulation of Nonprescription Drugs; S.2315 - Over-the-Counter Drug Safety, Innovation, and Reform Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KIND LLC via COVINGTON & BURLING LLP
2018 · third_quarter · Q3
Federal activity regarding food labeling claims
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES INC via COVINGTON & BURLING LLP
2018 · third_quarter · Q3
OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 1113), FDA Cosmetic Safety and Modernization Act (S. 2003), Modernization of Cosmetics Regulation Act of 2018 (Senate HELP Committee Discussion Draft), Over-the-Counter Drug Safety, Innovation and Reform Act (S. 2315), and Over-the-Counter Monograph Safety, Innovation and Reform Act of 2018 (H.R. 5333)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KIND LLC via COVINGTON & BURLING LLP
2018 · third_quarter · RR
Federal activity regarding food labeling claims
PERSONAL CARE PRODUCTS COUNCIL via COVINGTON & BURLING LLP
2018 · second_quarter · Q2
Consumer product safety issues related to potential amendments to the FDA's regulatory authorities over cosmetics, including S. 1113, Personal Care Products Safety Act, S. 2003, FDA Cosmetic Safety and Modernization Act; and Modernization of Cosmetics Regulation Act of 2018 (Senate HELP Committee Discussion Draft).
Filing targets: SENATE
CONSUMER HEALTHCARE PRODUCTS ASSOCIATION via COVINGTON & BURLING LLP
2018 · second_quarter · Q2
Regulation of Nonprescription Drugs; S.2315 - Over-the-Counter Drug Safety, Innovation, and Reform Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES INC via COVINGTON & BURLING LLP
2018 · second_quarter · Q2
OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 1113), FDA Cosmetic Safety and Modernization Act (S. 2003), Modernization of Cosmetics Regulation Act of 2018 (Senate HELP Committee Discussion Draft), Over-the-Counter Drug Safety, Innovation and Reform Act (S. 2315), and Over-the-Counter Monograph Safety, Innovation and Reform Act of 2018 (H.R. 5333)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES INC via COVINGTON & BURLING LLP
2018 · first_quarter · Q1
OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 1113), FDA Cosmetic Safety and Modernization Act (S. 2003), Modernization of Cosmetics Regulation Act of 2018 (Senate HELP Committee Discussion Draft), Over-the-Counter Drug Safety, Innovation and Reform Act (S. 2315), and Over-the-Counter Monograph Safety, Innovation and Reform Act of 2018 (H.R. 5333)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PERSONAL CARE PRODUCTS COUNCIL via COVINGTON & BURLING LLP
2018 · first_quarter · Q1
Consumer product safety issues related to potential amendments to the FDA's regulatory authorities over cosmetics, including S. 1113, Personal Care Products Safety Act, and S. 2003, FDA Cosmetic Safety and Modernization Act.
Filing targets: SENATE
PERSONAL CARE PRODUCTS COUNCIL via COVINGTON & BURLING LLP
2017 · fourth_quarter · Q4
Consumer product safety issues related to potential amendments to the FDA's regulatory authorities over cosmetics, including S. 1113, Personal Care Products Safety Act, and S. 2003, FDA Cosmetic Safety and Modernization Act.
Filing targets: SENATE
JOHNSON & JOHNSON SERVICES INC via COVINGTON & BURLING LLP
2017 · fourth_quarter · Q4
OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 1113) and FDA Cosmetic Safety and Modernization Act (S. 2003)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PERSONAL CARE PRODUCTS COUNCIL via COVINGTON & BURLING LLP
2017 · third_quarter · Q3
Consumer product safety issues related to potential amendments to the FDA's regulatory authorities over cosmetics, including S. 1113, Personal Care Products Safety Act
Filing targets: SENATE
JOHNSON & JOHNSON SERVICES INC via COVINGTON & BURLING LLP
2017 · third_quarter · Q3
OTC drugs and cosmetics reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PERSONAL CARE PRODUCTS COUNCIL via COVINGTON & BURLING LLP
2017 · second_quarter · Q2
Consumer product safety issues related to potential amendments to the FDA's regulatory authorities over cosmetics, including S. 1113, Personal Care Products Safety Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES INC via COVINGTON & BURLING LLP
2017 · second_quarter · 2A
OTC drugs and cosmetics reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PERSONAL CARE PRODUCTS COUNCIL via COVINGTON & BURLING LLP
2017 · second_quarter · RR
Activities related to potential cosmetics legislative reform.